
|Articles|July 21, 2017
GB Sciences Signs Consulting Services Agreement with Worldwide Clinical Trials, Inc.
Advertisement
GB Sciences, Inc. announced it has signed a consulting services agreement with Worldwide Clinical Trials, Inc. to assess the company's intellectual property portfolio and help with pre-IND planning for its cannabis-based formulations. Pre-IND consulting services will be performed by Michael F. Murphy, MD, PhD, chief medical and scientific officer (CMSO) of Worldwide Clinical Trials, Inc.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Approves GSK’s Exdensur for Severe Asthma Based on SWIFT Phase III Data
2
Rethinking Operational Models to Reduce Site Burden in 2026
3
What Patients Want from Remote Trials: New Survey Data Reveals Preferences Around Usability, Trust, and Participation
4
ACT Brief: Patient Preferences in Remote Trials, Sanofi’s Neurology and Immunology Deals, and AI-Driven Biomarkers in Oncology
5




